Engineered immune cells aim to tame stubborn IBD
NCT ID NCT07544160
First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This early-phase study tests a new treatment called ICG318 CAR-T for people with inflammatory bowel disease (IBD) that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and calm the overactive immune response causing IBD. The main goal is to check safety and find the best dose, with a key aim of helping patients achieve long-term remission without needing other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES (IBD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan people's hospital
Zhongshan, Guangdong, 528403, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.